Loading…
EXOCIN is a brand name for Ofloxacin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Exocin is indicated for the topical treatment of external ocular infections (such as conjunctivitis and keratoconjunctivitis) in adults and children caused by ofloxacin - sensitive organisms. Safety and efficacy in the treatment of ophthalmia neonatorum has not been established.
Verbatim from this product's MHRA label. Tap a section to expand.
Topical ocular instillation. For all ages: one to two drops in the affected eye(s) every two to four hours for the first two days and then four times daily. The length of treatment should not exceed ten days.
General Serious reactions after use of systemic ofloxacin are rare and most symptoms are reversible. Since a small amount of ofloxacin is systemically absorbed after topical administration, side-effects reported with systemic use could possibly occur.
Frequency categories:
Very common (≥1/10); Common (≥1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥1/10,000 to <1/1,000); Very rare (<1/10,000) and not known (cannot be estimated from the available data): Immune System Disorders: Very rare: Hypersensitivity* (including angioedema, dyspnea, anaphylactic reaction/shock, oropharyngeal swelling and tongue swollen).
* Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin. 4.
Nervous System Disorders Not known:
Dizziness Eye Disorders Common: Eye irritation; Ocular discomfort Not known: Keratitis; Conjunctivitis; Vision blurred; Photophobia; Eye oedema; Foreign body sensation in eyes; Lacrimation increased; Dry eye; Eye pain; Ocular hyperaemia; Hypersensitivity (including Eye pruritus and Eyelid pruritus).
Gastrointestinal Disorders Not known:
Nausea Skin and Subcutaneous Tissue Disorders Not Known: Periorbital oedema, Facial oedema
EXOCIN® is not for injection. Safety and effectiveness in infants below the age of one year have not been established. Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid) reactions, some following the first dose, have been reported in patients receiving systemic quinolones, including ofloxacin.
Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial oedema), airway obstruction, dyspnoea, urticaria, and itching. If an allergic reaction to EXOCIN® occurs, discontinue the drug.
Use EXOCIN® with caution in patients who have exhibited sensitivities to other quinolones antibacterial agents. When using EXOCIN® the risk of rhinopharyngeal passage which can contribute to the occurrence and the diffusion of bacterial resistance should be considered.
As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms. If worsening infection occurs, or if clinical improvement is not noted within a reasonable period, discontinue use and institute alternative therapy.
Stevens-Johnson syndrome has been reported in patients receiving topical ophthalmic ofloxacin, however, a causal relationship has not been established. Use EXOCIN® with caution in patients who have exhibited sensitivities to other quinolone antibacterial agents.
3% in the treatment of conjunctivitis in neonates. The use of EXOCIN® eye drops in neonates with ophthalmia neonatorum caused by Neisseria gonorrhoeae or Chlamydia trachomatis is not recommended as it has not been evaluated in such patients.
Use in elderly:
No comparative data are available with topical dosing in elderly versus other age groups. Clinical and non-clinical publications have reported the occurrence of corneal perforation in patients with pre-existing corneal epithelial defect or corneal ulcer, when treated with topical fluoroquinolone antibiotics.
EXOCIN® is contra-indicated in individuals who have shown hypersensitivity to ofloxacin, any of its excipients or any other quinolones.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ofloxacin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
g. g. rheumatoid arthritis), and concomitant use of ocular steroids or non-steroidal anti-inflammatory drugs. Nevertheless, it is necessary to advise caution regarding the risk of corneal perforation when using product to treat patients with corneal epithelial defects or corneal ulcers.
Corneal precipitates have been reported during treatment with topical ophthalmic ofloxacin. However, a causal relationship has not been established. Long-term, high-dose use of other fluoroquinolones in experimental animals has caused lenticular opacities.
However, this effect has not been reported in human patients, nor has it been noted following topical ophthalmic treatment with ofloxacin for up to six months in animal studies including studies in monkeys. EXOCIN® contains the preservative benzalkonium chloride which may cause ocular irritation and discolour soft contact lenses.
Sun or UV-exposition should be avoided during use of ofloxacin due to the potential for photosensitivity. Use of contact lenses is not recommended in patients receiving treatment for an eye infection.